Case Report: Probable blinatumomab-associated lung injury in a pediatric patient with B-ALL.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
Blinatumomab is a bispecific T Cell engager targeting CD3 and CD19. Initially approved for relapsed/refractory B Cell acute lymphoblastic leukemia (B-ALL), it was later extended to first-line B-ALL therapy. Despite its high efficacy, blinatumomab carries risks of adverse effects, including cytokine release syndrome and neurotoxicity. Blinatumomab-associated lung injury is exceptionally rare. We report a pediatric B-ALL patient who developed drug-induced lung injury following induction chemotherapy, with recurrence of lung injury after blinatumomab administration. The patient presented with dyspnea, hypoxemia, and radiographic findings suggestive of interstitial lung injury. After excluding infectious and other non-infectious etiologies, we considered blinatumomab-associated lung injury as the most likely diagnosis. Symptoms improved markedly following corticosteroid therapy. Clinicians should be alert to blinatumomab-associated lung injury, achieve early recognition and administer glucocorticoid intervention. A dose-escalation strategy facilitates successful rechallenge.